150 related articles for article (PubMed ID: 11917282)
1. Phase II: trial of twice weekly amifostine in patients with non-small cell lung cancer treated with chemoradiotherapy.
Werner-Wasik M; Axelrod RS; Friedland DP; Hauck W; Rose LJ; Chapman AE; Grubbs S; Deshields M; Curran WJ
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):34-9. PubMed ID: 11917282
[TBL] [Abstract][Full Text] [Related]
2. Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer.
Leong SS; Tan EH; Fong KW; Wilder-Smith E; Ong YK; Tai BC; Chew L; Lim SH; Wee J; Lee KM; Foo KF; Ang P; Ang PT
J Clin Oncol; 2003 May; 21(9):1767-74. PubMed ID: 12721253
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: radiation therapy oncology group trial 98-01.
Movsas B; Scott C; Langer C; Werner-Wasik M; Nicolaou N; Komaki R; Machtay M; Smith C; Axelrod R; Sarna L; Wasserman T; Byhardt R
J Clin Oncol; 2005 Apr; 23(10):2145-54. PubMed ID: 15800308
[TBL] [Abstract][Full Text] [Related]
4. Preliminary report on reduction of esophagitis by amifostine in patients with non-small-cell lung cancer treated with chemoradiotherapy.
Werner-Wasik M; Axelrod RS; Friedland DP; Hauck W; Rose LJ; Chapman AE; Grubbs S; DeShields M; Curran WJ
Clin Lung Cancer; 2001 May; 2(4):284-9; discussion 290. PubMed ID: 14720361
[TBL] [Abstract][Full Text] [Related]
5. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
[TBL] [Abstract][Full Text] [Related]
6. Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for stage III non-small-cell lung cancer: a California Cancer Consortium phase II trial.
Lau D; Leigh B; Gandara D; Edelman M; Morgan R; Israel V; Lara P; Wilder R; Ryu J; Doroshow J
J Clin Oncol; 2001 Jan; 19(2):442-7. PubMed ID: 11208837
[TBL] [Abstract][Full Text] [Related]
7. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer.
Antonadou D; Throuvalas N; Petridis A; Bolanos N; Sagriotis A; Synodinou M
Int J Radiat Oncol Biol Phys; 2003 Oct; 57(2):402-8. PubMed ID: 12957251
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase II study of amifostine mucosal protection by either subcutaneous injection or rapid IV bolus for patients with inoperable stage II-IIIA/B or stage IV non-small cell lung cancer with oligometastases receiving concurrent radiochemotherapy with carboplatin and paclitaxel followed by optional consolidative chemotherapy: a follow-up study after RTOG 98-01.
Werner-Wasik M; Langer C; Movsas B
Semin Oncol; 2004 Dec; 31(6 Suppl 18):47-51. PubMed ID: 15726523
[TBL] [Abstract][Full Text] [Related]
9. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy.
Werner-Wasik M; Pequignot E; Leeper D; Hauck W; Curran W
Int J Radiat Oncol Biol Phys; 2000 Oct; 48(3):689-96. PubMed ID: 11020565
[TBL] [Abstract][Full Text] [Related]
10. Induction paclitaxel and carboplatin followed by concurrent chemoradiotherapy in patients with unresectable, locally advanced non-small cell lung carcinoma: report of Fox Chase Cancer Center study 94-001.
Langer CJ; Movsas B; Hudes R; Schol J; Keenan E; Kilpatrick D; Yeung C; Curran W
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-89-S12-95. PubMed ID: 9331129
[TBL] [Abstract][Full Text] [Related]
11. Radiotherapy or chemotherapy followed by radiotherapy with or without amifostine in locally advanced lung cancer.
Antonadou D
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):50-8. PubMed ID: 11917285
[TBL] [Abstract][Full Text] [Related]
12. Effect of amifostine on toxicities associated with sequential chemotherapy and radiation therapy for unresectable non-small-cell lung cancer: results of a phase II trial.
Tannehill SP; Mehta MP; Larson M; Storer B; Pellet J; Kinsella TJ; Schiller JH
J Clin Oncol; 1997 Aug; 15(8):2850-7. PubMed ID: 9256128
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study).
Choy H; Devore RF; Hande KR; Porter LL; Rosenblatt P; Yunus F; Schlabach L; Smith C; Shyr Y; Johnson DH
Int J Radiat Oncol Biol Phys; 2000 Jul; 47(4):931-7. PubMed ID: 10863062
[TBL] [Abstract][Full Text] [Related]
14. High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial.
Rosenman JG; Halle JS; Socinski MA; Deschesne K; Moore DT; Johnson H; Fraser R; Morris DE
Int J Radiat Oncol Biol Phys; 2002 Oct; 54(2):348-56. PubMed ID: 12243807
[TBL] [Abstract][Full Text] [Related]
15. [Initial outcome of induction chemotherapy with weekly paclitaxel followed by three-dimensional conformal radiotherapy and concurrent weekly paclitaxel for stage III non-small cell lung cancer].
Wang WH; Bao Y; Chen M; Zhang L; Li KX; Xu GC; Deng XW; Lu TX; Cui NJ
Ai Zheng; 2006 Oct; 25(10):1279-83. PubMed ID: 17059776
[TBL] [Abstract][Full Text] [Related]
16. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer.
Choy H; Akerley W; Safran H; Graziano S; Chung C; Williams T; Cole B; Kennedy T
J Clin Oncol; 1998 Oct; 16(10):3316-22. PubMed ID: 9779707
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer.
Solomon B; Ball DL; Richardson G; Smith JG; Millward M; MacManus M; Michael M; Wirth A; O'Kane C; Muceniekas L; Ryan G; Rischin D
Lung Cancer; 2003 Sep; 41(3):353-61. PubMed ID: 12928126
[TBL] [Abstract][Full Text] [Related]
18. A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: preliminary findings.
Senzer N
Semin Oncol; 2002 Dec; 29(6 Suppl 19):38-41. PubMed ID: 12577242
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary results.
Komaki R; Lee JS; Kaplan B; Allen P; Kelly JF; Liao Z; Stevens CW; Fossella FV; Zinner R; Papadimitrakopoulou V; Khuri F; Glisson B; Pisters K; Kurie J; Herbst R; Milas L; Ro J; Thames HD; Hong WK; Cox JD
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):46-9. PubMed ID: 11917284
[TBL] [Abstract][Full Text] [Related]
20. Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC).
Kaplan B; Altýnbas M; Eroglu C; Karahacioglu E; Er O; Ozkan M; Bilgin M; Canoz O; Gulmez I; Gulec M
Am J Clin Oncol; 2004 Dec; 27(6):603-10. PubMed ID: 15577439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
